A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-09

AUTHORS

Jeffery P. Lamont, John Nemunaitis, Joseph A. Kuhn, Steven A. Landers, Todd M. McCarty

ABSTRACT

BACKGROUND: The E1-b attenuated adenovirus, ONYX-015 (Onyx Pharmaceuticals, Richmond, CA), has demonstrated antitumoral activity in patients with recurrent squamous cell carcinoma of the head and neck. This study evaluated the effects of intratumoral ONYX-015 injection combined with systemic chemotherapy. METHODS: Inclusion criteria included: (1) recurrent squamous cell carcinoma of the head and neck, not surgically salvageable, (2) target tumor amenable to direct injection, and (3) no prior chemotherapy for recurrent disease. Patients received ONYX-015 (10(10) plaque-forming units) intratumorally for 5 days, cisplatin (80 mg/m2) on day 1, and 5-fluorouracil (800-1000 mg/m2) on days 1-5. This cycle was repeated every 3 weeks. Serial physical examination and computed tomography were used to assess tumor size and treatment response. RESULTS: Fourteen patients were enrolled, and nine patients were evaluable for response at the time of enrollment. The mean age of the evaluable patients was 60.8 years (range, 46-71 years). Mean maximum tumor diameter was 4.8 cm (range, 1.9-10.5 cm). Treatment-related toxicity included nausea (n = 7, 77.8%), vomiting (n = 5, 55.6%), mucositis (n = 5, 55.6%), pain at the injection site (n = 5, 55.6%), constipation (n = 4, 44.4%), and fatigue (n = 4, 44.4%). Locoregional tumor control was obtained in all nine patients (100%) (mean observation time, 157 days). Complete clinical response was seen in three patients (33.3%), partial response was seen in three patients (33.3%), minor response was seen in one patient (11.1%), and two patients (22.2%) had stable disease. Median time to local progression of disease has not been reached (range, 35-356 days). CONCLUSIONS: ONYX-015 adenovirus plus systemic cisplatin and 5-fluorouracil provides antitumor activity and local tumor control in patients with recurrent squamous cell carcinoma of the head and neck. This novel treatment approach offers hope for patients with limited treatment alternatives and provides the foundation for a phase III clinical trial. More... »

PAGES

588-592

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf02725338

DOI

http://dx.doi.org/10.1007/bf02725338

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1035322328

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11005557


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenoviruses, Human", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Squamous Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Deletion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Head and Neck Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "From the Baylor University Medical Center and US Oncology, Dallas, Texas"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lamont", 
        "givenName": "Jeffery P.", 
        "id": "sg:person.010433213522.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010433213522.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "From the Baylor University Medical Center and US Oncology, Dallas, Texas"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nemunaitis", 
        "givenName": "John", 
        "id": "sg:person.01174440055.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174440055.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "From the Baylor University Medical Center and US Oncology, Dallas, Texas"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuhn", 
        "givenName": "Joseph A.", 
        "id": "sg:person.012723666452.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012723666452.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "From the Baylor University Medical Center and US Oncology, Dallas, Texas"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Landers", 
        "givenName": "Steven A.", 
        "id": "sg:person.01224254501.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224254501.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "From the Baylor University Medical Center and US Oncology, Dallas, Texas"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McCarty", 
        "givenName": "Todd M.", 
        "id": "sg:person.0645460600.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645460600.37"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1001/archotol.1992.01880050029006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001628072"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1101/gad.7.4.546", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004309332"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archsurg.1979.01370250041008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007687724"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/78638", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009134605", 
          "https://doi.org/10.1038/78638"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/78638", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009134605", 
          "https://doi.org/10.1038/78638"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1101/gad.7.4.535", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013372391"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1006/viro.1994.1480", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014199314"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1990.59", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021411975", 
          "https://doi.org/10.1038/bjc.1990.59"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1990.59", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021411975", 
          "https://doi.org/10.1038/bjc.1990.59"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm0697-639", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021949192", 
          "https://doi.org/10.1038/nm0697-639"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/88.8.519", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028427324"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1097-0347(200001)22:1<34::aid-hed6>3.0.co;2-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031683113"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0360-3016(76)90106-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032777514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.cgt.7700071", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043059277", 
          "https://doi.org/10.1038/sj.cgt.7700071"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.cgt.7700071", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043059277", 
          "https://doi.org/10.1038/sj.cgt.7700071"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.274.5286.373", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062554474"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1992.10.8.1245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077159197"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1992.10.2.257", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077377498"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1988.6.6.955", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079417711"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.annonc.a058906", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082397402"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082464016", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082791793", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1998.16.3.1054", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083229157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083347401", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-09", 
    "datePublishedReg": "2000-09-01", 
    "description": "BACKGROUND: The E1-b attenuated adenovirus, ONYX-015 (Onyx Pharmaceuticals, Richmond, CA), has demonstrated antitumoral activity in patients with recurrent squamous cell carcinoma of the head and neck. This study evaluated the effects of intratumoral ONYX-015 injection combined with systemic chemotherapy.\nMETHODS: Inclusion criteria included: (1) recurrent squamous cell carcinoma of the head and neck, not surgically salvageable, (2) target tumor amenable to direct injection, and (3) no prior chemotherapy for recurrent disease. Patients received ONYX-015 (10(10) plaque-forming units) intratumorally for 5 days, cisplatin (80 mg/m2) on day 1, and 5-fluorouracil (800-1000 mg/m2) on days 1-5. This cycle was repeated every 3 weeks. Serial physical examination and computed tomography were used to assess tumor size and treatment response.\nRESULTS: Fourteen patients were enrolled, and nine patients were evaluable for response at the time of enrollment. The mean age of the evaluable patients was 60.8 years (range, 46-71 years). Mean maximum tumor diameter was 4.8 cm (range, 1.9-10.5 cm). Treatment-related toxicity included nausea (n = 7, 77.8%), vomiting (n = 5, 55.6%), mucositis (n = 5, 55.6%), pain at the injection site (n = 5, 55.6%), constipation (n = 4, 44.4%), and fatigue (n = 4, 44.4%). Locoregional tumor control was obtained in all nine patients (100%) (mean observation time, 157 days). Complete clinical response was seen in three patients (33.3%), partial response was seen in three patients (33.3%), minor response was seen in one patient (11.1%), and two patients (22.2%) had stable disease. Median time to local progression of disease has not been reached (range, 35-356 days).\nCONCLUSIONS: ONYX-015 adenovirus plus systemic cisplatin and 5-fluorouracil provides antitumor activity and local tumor control in patients with recurrent squamous cell carcinoma of the head and neck. This novel treatment approach offers hope for patients with limited treatment alternatives and provides the foundation for a phase III clinical trial.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf02725338", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1105545", 
        "issn": [
          "1068-9265", 
          "1534-4681"
        ], 
        "name": "Annals of Surgical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "name": "A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the baylor experience)", 
    "pagination": "588-592", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "a8425b189dede4725f03129c516e71a270e10ea2e7ca9beb27ba6573c9d80207"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11005557"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9420840"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf02725338"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1035322328"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf02725338", 
      "https://app.dimensions.ai/details/publication/pub.1035322328"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000489.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF02725338"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf02725338'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf02725338'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf02725338'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf02725338'


 

This table displays all metadata directly associated to this object as RDF triples.

233 TRIPLES      21 PREDICATES      68 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf02725338 schema:about N1ad2926c28c843aaa5572342241b0021
2 N1fe28cf7d7244d68a32b0a4295b6cc1b
3 N28695809a2204e3b903a546c1a490f64
4 N30040ec2a0514249a3abafca1aac48e4
5 N36a7b964fc2a4eefbcf416fd447eb454
6 N3c891d4a3da044b3adb43124bed31947
7 N5b403d30b1df42938280c930dc6a63b9
8 N73fe9562874a48e98fff8d0f5d1a0295
9 Nabc19d4e2cfb4fecb96d7519f3803293
10 Nbb735e964a2644cbaab915d438a78bb5
11 Nc6cbca991e344e40b8048093a31d26e6
12 Nc93390d20c814af187060866b2dece30
13 Ncc6450906aef4bfe8897af76ee6fef17
14 Nd20b2b13c01545e389bf15ebaa854ee9
15 Ne6bd00db265c468d951721aa0d0ae741
16 Ne7daeb0ec886460db006992ea0020c60
17 Ne9e6be93590044b09b979ecc58886d73
18 Nf479eda06b94425a9d1e4d2aa04e5df4
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author N467a07326eff4dff9cabe4ab2b584720
22 schema:citation sg:pub.10.1038/78638
23 sg:pub.10.1038/bjc.1990.59
24 sg:pub.10.1038/nm0697-639
25 sg:pub.10.1038/sj.cgt.7700071
26 https://app.dimensions.ai/details/publication/pub.1082464016
27 https://app.dimensions.ai/details/publication/pub.1082791793
28 https://app.dimensions.ai/details/publication/pub.1083347401
29 https://doi.org/10.1001/archotol.1992.01880050029006
30 https://doi.org/10.1001/archsurg.1979.01370250041008
31 https://doi.org/10.1002/(sici)1097-0347(200001)22:1<34::aid-hed6>3.0.co;2-3
32 https://doi.org/10.1006/viro.1994.1480
33 https://doi.org/10.1016/0360-3016(76)90106-1
34 https://doi.org/10.1093/jnci/88.8.519
35 https://doi.org/10.1093/oxfordjournals.annonc.a058906
36 https://doi.org/10.1101/gad.7.4.535
37 https://doi.org/10.1101/gad.7.4.546
38 https://doi.org/10.1126/science.274.5286.373
39 https://doi.org/10.1200/jco.1988.6.6.955
40 https://doi.org/10.1200/jco.1992.10.2.257
41 https://doi.org/10.1200/jco.1992.10.8.1245
42 https://doi.org/10.1200/jco.1998.16.3.1054
43 schema:datePublished 2000-09
44 schema:datePublishedReg 2000-09-01
45 schema:description BACKGROUND: The E1-b attenuated adenovirus, ONYX-015 (Onyx Pharmaceuticals, Richmond, CA), has demonstrated antitumoral activity in patients with recurrent squamous cell carcinoma of the head and neck. This study evaluated the effects of intratumoral ONYX-015 injection combined with systemic chemotherapy. METHODS: Inclusion criteria included: (1) recurrent squamous cell carcinoma of the head and neck, not surgically salvageable, (2) target tumor amenable to direct injection, and (3) no prior chemotherapy for recurrent disease. Patients received ONYX-015 (10(10) plaque-forming units) intratumorally for 5 days, cisplatin (80 mg/m2) on day 1, and 5-fluorouracil (800-1000 mg/m2) on days 1-5. This cycle was repeated every 3 weeks. Serial physical examination and computed tomography were used to assess tumor size and treatment response. RESULTS: Fourteen patients were enrolled, and nine patients were evaluable for response at the time of enrollment. The mean age of the evaluable patients was 60.8 years (range, 46-71 years). Mean maximum tumor diameter was 4.8 cm (range, 1.9-10.5 cm). Treatment-related toxicity included nausea (n = 7, 77.8%), vomiting (n = 5, 55.6%), mucositis (n = 5, 55.6%), pain at the injection site (n = 5, 55.6%), constipation (n = 4, 44.4%), and fatigue (n = 4, 44.4%). Locoregional tumor control was obtained in all nine patients (100%) (mean observation time, 157 days). Complete clinical response was seen in three patients (33.3%), partial response was seen in three patients (33.3%), minor response was seen in one patient (11.1%), and two patients (22.2%) had stable disease. Median time to local progression of disease has not been reached (range, 35-356 days). CONCLUSIONS: ONYX-015 adenovirus plus systemic cisplatin and 5-fluorouracil provides antitumor activity and local tumor control in patients with recurrent squamous cell carcinoma of the head and neck. This novel treatment approach offers hope for patients with limited treatment alternatives and provides the foundation for a phase III clinical trial.
46 schema:genre research_article
47 schema:inLanguage en
48 schema:isAccessibleForFree false
49 schema:isPartOf N628a3dccd4094b10b5f142b90c04efd4
50 N63115834c21540b0bcc40534b71ce8c1
51 sg:journal.1105545
52 schema:name A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the baylor experience)
53 schema:pagination 588-592
54 schema:productId N512c8916519d4494a092f2669836700e
55 N5fda177ddf9b42458c3abf27b6f5f35a
56 N8432041a63564944aa53aa3ec950c9a6
57 Na9a12f765258447b810c13aa4b63325e
58 Nd58cb15998bc419ba9fded81e4f72daf
59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035322328
60 https://doi.org/10.1007/bf02725338
61 schema:sdDatePublished 2019-04-10T20:42
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher N0bf8e7d243a04a91965611eed4a034d6
64 schema:url http://link.springer.com/10.1007/BF02725338
65 sgo:license sg:explorer/license/
66 sgo:sdDataset articles
67 rdf:type schema:ScholarlyArticle
68 N0bf8e7d243a04a91965611eed4a034d6 schema:name Springer Nature - SN SciGraph project
69 rdf:type schema:Organization
70 N1ad2926c28c843aaa5572342241b0021 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Cisplatin
72 rdf:type schema:DefinedTerm
73 N1b06802cb8c344e397999911814b0c94 rdf:first sg:person.012723666452.11
74 rdf:rest N6f50c9f522e9439b813db21cdb1cc169
75 N1fe28cf7d7244d68a32b0a4295b6cc1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Injections
77 rdf:type schema:DefinedTerm
78 N28695809a2204e3b903a546c1a490f64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Genetic Therapy
80 rdf:type schema:DefinedTerm
81 N30040ec2a0514249a3abafca1aac48e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Male
83 rdf:type schema:DefinedTerm
84 N36a7b964fc2a4eefbcf416fd447eb454 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Humans
86 rdf:type schema:DefinedTerm
87 N3c891d4a3da044b3adb43124bed31947 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Middle Aged
89 rdf:type schema:DefinedTerm
90 N467a07326eff4dff9cabe4ab2b584720 rdf:first sg:person.010433213522.38
91 rdf:rest Ndebe2d59cf8044c2a758fabfdbab08fd
92 N512c8916519d4494a092f2669836700e schema:name doi
93 schema:value 10.1007/bf02725338
94 rdf:type schema:PropertyValue
95 N5b403d30b1df42938280c930dc6a63b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Carcinoma, Squamous Cell
97 rdf:type schema:DefinedTerm
98 N5fda177ddf9b42458c3abf27b6f5f35a schema:name dimensions_id
99 schema:value pub.1035322328
100 rdf:type schema:PropertyValue
101 N628a3dccd4094b10b5f142b90c04efd4 schema:issueNumber 8
102 rdf:type schema:PublicationIssue
103 N63115834c21540b0bcc40534b71ce8c1 schema:volumeNumber 7
104 rdf:type schema:PublicationVolume
105 N6f50c9f522e9439b813db21cdb1cc169 rdf:first sg:person.01224254501.66
106 rdf:rest Ne493959309d344bfaa7b5acfccb7c3c0
107 N73fe9562874a48e98fff8d0f5d1a0295 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Fluorouracil
109 rdf:type schema:DefinedTerm
110 N8432041a63564944aa53aa3ec950c9a6 schema:name nlm_unique_id
111 schema:value 9420840
112 rdf:type schema:PropertyValue
113 Na9a12f765258447b810c13aa4b63325e schema:name pubmed_id
114 schema:value 11005557
115 rdf:type schema:PropertyValue
116 Nabc19d4e2cfb4fecb96d7519f3803293 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Female
118 rdf:type schema:DefinedTerm
119 Nbb735e964a2644cbaab915d438a78bb5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Head and Neck Neoplasms
121 rdf:type schema:DefinedTerm
122 Nc6cbca991e344e40b8048093a31d26e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Antineoplastic Combined Chemotherapy Protocols
124 rdf:type schema:DefinedTerm
125 Nc93390d20c814af187060866b2dece30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Adenoviruses, Human
127 rdf:type schema:DefinedTerm
128 Ncc6450906aef4bfe8897af76ee6fef17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Neoplasm Recurrence, Local
130 rdf:type schema:DefinedTerm
131 Nd20b2b13c01545e389bf15ebaa854ee9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Disease Progression
133 rdf:type schema:DefinedTerm
134 Nd58cb15998bc419ba9fded81e4f72daf schema:name readcube_id
135 schema:value a8425b189dede4725f03129c516e71a270e10ea2e7ca9beb27ba6573c9d80207
136 rdf:type schema:PropertyValue
137 Ndebe2d59cf8044c2a758fabfdbab08fd rdf:first sg:person.01174440055.45
138 rdf:rest N1b06802cb8c344e397999911814b0c94
139 Ne493959309d344bfaa7b5acfccb7c3c0 rdf:first sg:person.0645460600.37
140 rdf:rest rdf:nil
141 Ne6bd00db265c468d951721aa0d0ae741 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Aged
143 rdf:type schema:DefinedTerm
144 Ne7daeb0ec886460db006992ea0020c60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Antimetabolites, Antineoplastic
146 rdf:type schema:DefinedTerm
147 Ne9e6be93590044b09b979ecc58886d73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Remission Induction
149 rdf:type schema:DefinedTerm
150 Nf479eda06b94425a9d1e4d2aa04e5df4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Gene Deletion
152 rdf:type schema:DefinedTerm
153 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
154 schema:name Medical and Health Sciences
155 rdf:type schema:DefinedTerm
156 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
157 schema:name Oncology and Carcinogenesis
158 rdf:type schema:DefinedTerm
159 sg:journal.1105545 schema:issn 1068-9265
160 1534-4681
161 schema:name Annals of Surgical Oncology
162 rdf:type schema:Periodical
163 sg:person.010433213522.38 schema:affiliation https://www.grid.ac/institutes/grid.420754.0
164 schema:familyName Lamont
165 schema:givenName Jeffery P.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010433213522.38
167 rdf:type schema:Person
168 sg:person.01174440055.45 schema:affiliation https://www.grid.ac/institutes/grid.420754.0
169 schema:familyName Nemunaitis
170 schema:givenName John
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174440055.45
172 rdf:type schema:Person
173 sg:person.01224254501.66 schema:affiliation https://www.grid.ac/institutes/grid.420754.0
174 schema:familyName Landers
175 schema:givenName Steven A.
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224254501.66
177 rdf:type schema:Person
178 sg:person.012723666452.11 schema:affiliation https://www.grid.ac/institutes/grid.420754.0
179 schema:familyName Kuhn
180 schema:givenName Joseph A.
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012723666452.11
182 rdf:type schema:Person
183 sg:person.0645460600.37 schema:affiliation https://www.grid.ac/institutes/grid.420754.0
184 schema:familyName McCarty
185 schema:givenName Todd M.
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645460600.37
187 rdf:type schema:Person
188 sg:pub.10.1038/78638 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009134605
189 https://doi.org/10.1038/78638
190 rdf:type schema:CreativeWork
191 sg:pub.10.1038/bjc.1990.59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021411975
192 https://doi.org/10.1038/bjc.1990.59
193 rdf:type schema:CreativeWork
194 sg:pub.10.1038/nm0697-639 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021949192
195 https://doi.org/10.1038/nm0697-639
196 rdf:type schema:CreativeWork
197 sg:pub.10.1038/sj.cgt.7700071 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043059277
198 https://doi.org/10.1038/sj.cgt.7700071
199 rdf:type schema:CreativeWork
200 https://app.dimensions.ai/details/publication/pub.1082464016 schema:CreativeWork
201 https://app.dimensions.ai/details/publication/pub.1082791793 schema:CreativeWork
202 https://app.dimensions.ai/details/publication/pub.1083347401 schema:CreativeWork
203 https://doi.org/10.1001/archotol.1992.01880050029006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001628072
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1001/archsurg.1979.01370250041008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007687724
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1002/(sici)1097-0347(200001)22:1<34::aid-hed6>3.0.co;2-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031683113
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1006/viro.1994.1480 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014199314
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1016/0360-3016(76)90106-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032777514
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1093/jnci/88.8.519 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028427324
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1093/oxfordjournals.annonc.a058906 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082397402
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1101/gad.7.4.535 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013372391
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1101/gad.7.4.546 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004309332
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1126/science.274.5286.373 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062554474
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1200/jco.1988.6.6.955 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079417711
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1200/jco.1992.10.2.257 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077377498
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1200/jco.1992.10.8.1245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077159197
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1200/jco.1998.16.3.1054 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083229157
230 rdf:type schema:CreativeWork
231 https://www.grid.ac/institutes/grid.420754.0 schema:alternateName US Oncology Network
232 schema:name From the Baylor University Medical Center and US Oncology, Dallas, Texas
233 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...